Recent reports have provided evidence that the extracellular domain of CA IX can be released into body fluids and serve as a prognostic biomarker in patients with renal cell carcinoma [17], breast cancer [18], non-small cell lung cancer [19], or rectal cancer [20]. This evidence concerns the gene CA9 and renal cell carcinoma.